Pangu Bispecific Antibodies
Oncology (NRP2-focused)
Research/PreclinicalDiscovery and platform development
Key Facts
Indication
Oncology (NRP2-focused)
Phase
Research/Preclinical
Status
Discovery and platform development
Company
About aTyr Pharma
aTyr Pharma is translating the groundbreaking discovery of extracellular tRNA synthetase biology into a new class of protein-based therapeutics for fibrosis and inflammation. Its lead asset, efzofitimod, has reported Phase 3 topline results in pulmonary sarcoidosis and is in a Phase 2 study for SSc-ILD, targeting diseases with high unmet need. The company's strategy is to advance its proprietary platform to generate a pipeline of immunomodulators while exploring bispecific antibody opportunities through its Pangu BioPharma subsidiary.
View full company profile